Real World Exposure-Response Relationship of Vedolizumab in Inflammatory Bowel Disease: A Pooled Multicenter Observational Cohort Analysis of Clinical and Modeled Pharmacological Data

被引：0
|
作者：
Vande Casteele, Niels [1 ]
Sandborn, William J. [1 ]
Feagan, Brian G. [2 ,3 ,4 ]
Vermeire, Severine [5 ]
Dulai, Parambir S. [1 ]
Panes, Julian [6 ]
Yarur, Andres [7 ]
Roblin, Xavier [8 ]
Ben-Horin, Shomron [9 ,10 ]
Dotan, Iris [11 ]
Osterman, Mark [12 ]
Lindner, Dirk [13 ]
Agboton, Christian [13 ]
Rosario, Maria [14 ]
Osborn, Teresa [15 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Robarts Clin Trials Inc, Amsterdam, Netherlands
[3] Acad Med Ctr, Amsterdam, Netherlands
[4] Western Univ, London, ON, Canada
[5] Univ Hosp Leuven, Leuven, Vlaams Brabant, Belgium
[6] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Catalonia, Spain
[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[8] Ctr Hosp Univ St Etienne, St Etienne, Auvergne, France
[9] Sheba Med Ctr, Tel Hashomer, Israel
[10] Tel Aviv Univ, Tel Aviv, Israel
[11] Rabin Med Ctr, Tel Aviv, Israel
[12] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[13] Takeda, Zurich, Switzerland
[14] Takeda, Cambridge, MA USA
[15] Takeda, Chicago, IL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2020年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S0652
引用
收藏
页码：S327 / S327
页数：1
相关论文
共 50 条
  • [1] Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study
    Vande Casteele, Niels
    Sandborn, William J.
    Feagan, Brian G.
    Vermeire, Severine
    Dulai, Parambir S.
    Yarur, Andres
    Roblin, Xavier
    Ben-Horin, Shomron
    Dotan, Iris
    Osterman, Mark T.
    Rosario, Maria
    Osborn, Teresa McRorie
    Panes, Julian
    Lindner, Dirk
    Agboton, Christian
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (03) : 463 - 476
  • [2] EARLY VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL RESPONSE IN A "REAL WORLD" PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
    Bonthala, Nirupama
    Morganstern, Bradley
    Mengesha, Emebet
    Landers, Carol
    Mould, Diane R.
    Li, Dalin
    Vasiliauskas, Eric
    Targan, Stephan R.
    McGovern, Dermot P. B.
    Melmed, Gil
    GASTROENTEROLOGY, 2020, 158 (06) : S465 - S466
  • [3] Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
    Plevris, N.
    Chuah, C. S.
    Allen, R. M.
    Arnott, I. D.
    Brennan, P. N.
    Chaudhary, S.
    Churchhouse, A. M. D.
    Din, S.
    Donoghue, E.
    Gaya, D. R.
    Groome, M.
    Jafferbhoy, H. M.
    Jenkinson, P. W.
    Lam, W. L.
    Lyons, M.
    Macdonald, J. C.
    MacMaster, M.
    Mowat, C.
    Naismith, G. D.
    Potts, L. F.
    Saffouri, E.
    Seenan, J. P.
    Sengupta, A.
    Shasi, P.
    Sutherland, D. I.
    Todd, J. A.
    Veryan, J.
    Watson, A. J. M.
    Watts, D. A.
    Jones, G. R.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (09): : 1111 - 1120
  • [4] REAL WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, L.
    Mosli, M.
    Hather, Greg
    Demuth, Dirk
    Blake, Aimee
    Curtis, R.
    Khalid, Mona
    Loftus, Edward V.
    INTERNIST, 2018, 59 : S55 - S56
  • [5] Vedolizumab Achieves Corticosteroid-Free Clinical Response and Remission in Inflammatory Bowel Disease: A Real World Meta-Analysis
    Shaw, Caroline
    Brown, Rebecca
    Wang, Song
    Adsul, Shashi
    Agboton, Christian
    Kamble, Pravin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S345 - S345
  • [6] Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Jessica R. Allegretti
    Edward L. Barnes
    Betsey Stevens
    Margaret Storm
    Ashwin Ananthakrishnan
    Vijay Yajnik
    Joshua Korzenik
    Digestive Diseases and Sciences, 2017, 62 : 1590 - 1596
  • [7] Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Allegretti, Jessica R.
    Barnes, Edward L.
    Stevens, Betsey
    Storm, Margaret
    Ananthakrishnan, Ashwin
    Yajnik, Vijay
    Korzenik, Joshua
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (06) : 1590 - 1596
  • [8] The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naive patients with inflammatory bowel disease - a multicenter European real world experience
    Kopylov, U.
    Sebastian, S.
    Ron, Y.
    Steinhagen, P. R.
    Roblin, X.
    Pugliese, D.
    Shitrit, A. Bar-Gil
    Katsanos, K.
    Fiorino, G.
    Allocca, M.
    Sipponen, T.
    Ungar, B.
    Armuzzi, A.
    Eliakim, R.
    Christodoulou, D.
    Baumgart, D. C.
    Ben-Horin, S.
    Dotan, I.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S264 - S265
  • [9] REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, Laurent
    Mosli, Mahmoud
    Hather, Greg
    Demuth, Dirk
    Blake, Aimee
    Curtis, Rebecca
    Khalid, Javaria Mona
    Loftus, Edward V., Jr.
    GASTROENTEROLOGY, 2018, 154 (01) : S82 - S82
  • [10] REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, Laurent
    Mosli, Mahmoud
    Hather, Greg
    Demuth, Dirk
    Blake, Aimee
    Curtis, Rebecca
    Khalid, Javaria Mona
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S57 - S58
12345